2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma

BACKGROUND: Both everolimus and axitinib are approved for patients with metastatic renal cell carcinoma (mRCC) in second-line therapy. Currently, there are no comparative clinical trials reported. PURPOSE: The objective of this study is to assess the effectiveness and safety of everolimus vs axitini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Collado-Borrell, R, Escudero-Vilaplana, V, Ortega-Navarro, C, García-Martín, E, Herranz-Alonso, A, Sanjurjo-Saez, M
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 2: Selection, procurement and distribution
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535217/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.28
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados